Table 1.
Cohort Demographics at Time of First TE Assessmenta
| Age, years | 46.5 (41.1–52.2) |
| Sex, n (%) | |
| Male | 67 (95.7) |
| Female | 3 (4.3) |
| Known duration HIV positive, years | 16.7 (8.4–22.8) |
| Ethnicity n (%) | |
| Caucasian | 60 (85.7) |
| Asian | 4 (5.7) |
| African | 4 (5.7) |
| Hispanic | 2 (2.9) |
| CD4 nadir, cells/µL | 284 (137–507) |
| Duration on cART, years | 10.7 (3.5–13.5) |
| Duration on HBV-active cART, years | 7.8 (3.3–11.7) |
| On HBV-active cART, % (n) | 91.4 (64) |
| HIV RNA positive (>50 copies/mL), % | 25.4 |
| HIV RNA, log10 copies/mL | 1.5 (1.3–1.7) |
| HBV DNA positive, % | 25.4 |
| HBV DNA, log10 IU/mL | 1.4 (1.3–2.6) |
| HBeAg positive, % | 29.2 |
| Most recent HCV Ab test positive, % | 28.6 |
| Most recent HCV RNA test positive, % | 22.9 |
| CD4 count, cells/µL | 381 (187–606) |
| CD4 count, % | 20.5 (14.0–31.3) |
| ALT, IU/mL | 34 (21–50) |
| Platelets, per mL | 185 (142–232) |
| 1st TE, kPa | 6.0 (4.8–10.3) |
| 1st TE, fibrosis stage | 2 (1–4) |
| 1st TE fibrosis, stage % | |
| F1 | 48.6 |
| F2 | 15.7 |
| F3 | 7.1 |
| F4 | 28.6 |
| Fibrosis classified as mild-moderate (≤F2), n (%) | 45 (64.3) |
Abbreviations: Ab, antibody; Ag, antigen; ALT, alanine transaminase; cART, combination antiretroviral therapy; DNA, deoxyribonucleic acid; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IQR, interquartile range; RNA, ribonucleic acid; TE, vibration-controlled transient elastography.
a All data presented as median (IQR) unless otherwise stated. First TE assessments performed during the period 2008–2011.